{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-000420","form_type":"8-K","ticker":"SNOA","cik":"0001367083","company_name":"Sonoma Pharmaceuticals, Inc.","filed_at":"2023-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.635664+00:00","generated_at":"2026-06-20T05:10:55.262473+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sonoma enters exclusive South Korea distribution deal with Daewoong for Primocyn","bullets":["Exclusive distribution agreement effective Jan 26, 2023 for Primocyn Skin Solution (Microcyn technology) in South Korea.","Initial term of two years, automatically renewing for two-year periods unless terminated.","Daewoong responsible for obtaining marketing authorization and all regulatory clearances in the territory.","Minimum purchase thresholds (redacted) required to maintain exclusivity beyond second year; initial fee also redacted.","Sonoma to provide registration dossier within 90 days; Daewoong to apply for marketing authorization."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-000420","json":"https://secwatch.observer/filing/0001683168-23-000420.json","markdown":"https://secwatch.observer/filing/0001683168-23-000420.md","text":"https://secwatch.observer/filing/0001683168-23-000420.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367083/000168316823000420/0001683168-23-000420-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367083/000168316823000420/sonoma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T05:10:55.262473+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"29adc87d1ef8af1e5e5540da86faf185dc1e1ba8","claim":"Sonoma Pharmaceuticals, Inc. entered into Exclusive Distribution Agreement with Daewoong Pharmaceutical Co., Ltd. valued at Exclusive distribution agreement for Primocyn Skin Solution products containing Microcyn technology (effective 2023-01-26).","evidence_excerpt":"Effective January 26, 2023, we entered into an exclusive distribution agreement with Daewoong Pharmaceutical Co., Ltd. for the marketing and distribution of Primocyn TM Skin Solution products, containing our Microcyn® technology, in South Korea.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367083/000168316823000420/0001683168-23-000420-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Daewoong Pharmaceutical Co., Ltd."},{"label":"Value","value":"Exclusive distribution agreement for Primocyn Skin Solution products containing Microcyn technology"},{"label":"Effective","value":"2023-01-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}